PreviousLimFlow Announces Positive Six-month Data From PROMISE I U.S. Early Feasibility Study Demonstrating Excellent Amputation Free Survival and Wound Healing in No-option Patient Population
NextLimflow Receives FDA Approval for U.S. Pivotal Study of Minimally-Invasive Technology Designed to Prevent Amputations in Chronic Limb-Threatening Ischemia Patients
